104
Participants
Start Date
September 19, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Semaglutide 14 MG [Rybelsus]
At baseline participants will initiate treatment with 3mg of oral semaglutide dosing from weeks 1 to 4. Depending on tolerability the dose will increase to 7 mg daily from weeks 5 to 8 and 14 mg from week 9. Trial medication will be dispensed to subjects for the first time immediately after randomisation and adjusted week 5 and week 9.
Placebo
Saline
RECRUITING
Department og Nephrology and Endocrinology, Rigshospitalet, Copenhagen
Aarhus University Hospital
OTHER
Odense University Hospital
OTHER
Rigshospitalet, Denmark
OTHER